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Abstract 23 
Since the 1970s, the role of infectious diseases in the pathogenesis of Graves’ disease 24 
(GD) has been an object of intensive research. The last decade has witnessed many 25 
studies on Yersinia enterocolitica, Helicobacter pylori and other bacterial organisms 26 
and their potential impact on GD. Retrospective, prospective and molecular binding 27 
studies have been performed with contrary outcomes. Until now it is not clear whether 28 
bacterial infections can trigger autoimmune thyroid disease. Common risk factors for 29 
GD (gender, smoking, stress, and pregnancy) reveal profound changes in the bacterial 30 
communities of the gut compared to that of healthy controls but a pathogenetic link 31 
between GD and dysbiosis has not yet been fully elucidated. Conventional bacterial 32 
culture, in vitro models, next generation and high-throughput DNA sequencing are 33 
applicable methods to assess the impact of bacteria in disease onset and 34 
development. Further studies on the involvement of bacteria in GD are needed and 35 
may contribute to the understanding of pathogenetic processes. This review will 36 
examine available evidence on the subject. 37 
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Abbreviations 46 
AITD  autoimmune thyroid disease 47 
Anti-Tg Antithyroglobulin 48 
CagA  Cytotoxin-associated gene A 49 
CD  Celiac disease 50 
DES  Dry eye syndrome 51 
ELISA  Enzyme-linked immunosorbent assay 52 
GD  Graves’ disease 53 
GF  Germ free  54 
GO  Graves’ orbitopathy 55 
HAT  Hashimoto thyroiditis 56 
HLA  Human leukocyte antigen 57 
HP  Helicobacter pylori 58 
HPA  Hypothalamic-pituitary-adrenal axis 59 
HUVEC Human umbilical vein endothelial cells 60 
IBD  Inflammatory bowel disease 61 
IFAA  Immunofluorescent antibody assay  62 
NOD  Non-obese diabetic  63 
PBMC Peripheral blood mononuclear cells 64 
PM  Pretibial myxedema 65 
RA  Rheumatoid arthritis 66 
SCFA  Small chain fatty acid 67 
SHIME Simulator of human intestinal microbial ecosystem 68 
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SPF  Specific pathogen free 69 
T1D  Type 1 diabetes 70 
TGF-β Transforming growth factor beta 71 
TIM  TNO (gastro-) intestinal model  72 
TPO  Thyroperoxidase 73 
Tregs  Regulatory T cells 74 
TSAb  TSH receptor stimulating antibodies  75 
TSBAb TSH-stimulation blocking antibody 76 
TSHR  TSH receptor 77 
rlUBT  Radiolabeled urea breath test  78 
WB  Western blot 79 
YE  Yersinia enterocolitica 80 
  81 
5 
1. Introduction 82 
Bacteria and bacterial antigens have long been considered as possible culprits in 83 
inducing autoimmune disease. Using the example of rheumatic fever, the link between 84 
bacteria and disease was established at the end of the 19th century by Triboulet and 85 
Coyon [1] and several decades later, experimental and clinical data indicated that 86 
autoimmunity in rheumatic fever is induced in response to group A streptococci [2]. 87 
Current mechanisms suggested to lead to autoimmune processes after a bacterial 88 
infection include molecular mimicry, epitope spreading, bystander activation and 89 
cryptic antigens [3].  90 
In autoimmune thyroid diseases (AITD), especially Hashimoto thyroiditis (HT) and 91 
Graves’ disease (GD), evidence for possible bacterial involvement in onset and 92 
progression is based solely on retrospective measures of bacterial antibodies in AITD 93 
patients (Table 1). These include the bacteria Yersinia enterocolitica, Helicobacter 94 
pylori and Borrelia burgdorferi (Figure 1). As in rheumatic fever, several tissues are 95 
targeted by the autoimmune response in GD (mainly thyroid, but also adipose tissue, 96 
skin and bone) and the whole body is affected by the hyperthyroid state. There has 97 
been limited examination of the possible connection between AITD and the microbiota 98 
using only serological methods. Other methods such as in vitro models, 16S rRNA 99 
gene sequencing, next generation sequencing and high throughput sequencing have 100 
already been applied to investigate the role of bacteria in other autoimmune diseases, 101 
but not in AITD. These platforms allow characterization of the microbiota from AITD 102 
affected areas (eyes) or areas adjacent to them (nose, mouth, skin) and contributing 103 
factors such as genetic predisposition and environmental factors associated with AITD. 104 
The role of microorganisms in the development of AITD is still controversial and not 105 
fully elucidated. An understanding of the precise mechanisms of interaction between 106 
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bacterial agents in inducing thyroid autoimmunity could result in the development of 107 
new strategies for prevention and treatment. 108 
This review aims to summarize current knowledge on the role of the microbiota in 109 
thyroid autoimmunity and will focus on the bacterial component. 110 
 111 
2. Autoimmune thyroid disease 112 
Autoimmune disorders are a broad range of related diseases in which inappropriate 113 
immune responses of the body arise against its own cells, tissue and organs, resulting 114 
in inflammation and damage. This response may affect only a particular tissue/organ 115 
of the body (such as in autoimmune thyroiditis) or may be systemic (such as systemic 116 
lupus erythematosus). In autoimmunity, the balance between proinflammatory and 117 
regulatory mechanisms, as a requirement for sufficient tolerance of the body against 118 
its own cells, is no longer maintained. Autoimmune reactions are characterized by the 119 
appearance of autoreactive B and T cells, which can be activated via other cells and 120 
which are very specific. Several different AITDs exist, but Hashimoto´s thyroiditis (HT) 121 
and Graves’ disease (GD) are the most prevalent [4]. Approximately 5% of the 122 
population is affected with HT and the disease is usually diagnosed in the fourth to 123 
sixth decade of life [5]. Graves’ disease is the underlying cause of 50 to 80% of 124 
hyperthyroidism and affects approximately 0.5% of the population [6, 7]. The incidence 125 
of GD is around 0.5 per 1000 annually in England [8] and 0.77 per 1000 in women and 126 
0.14 per 1000 in men, respectively, in Scotland [9]. AITDs are the most common organ-127 
specific autoimmune diseases and affect more women than men, with a female-to-128 
male ratio from 5 to 10 [10].  129 
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Hashimoto's thyroiditis, also known as autoimmune or chronic lymphocytic thyroiditis, 130 
is characterized by infiltration of the thyroid gland by inflammatory cells, subsequent 131 
atrophy of the thyroid tissue [11] and production of antithyroid antibodies, especially 132 
against thyroperoxidase (anti-TPO), antithyroglobulin (anti-Tg) and TSH-stimulation 133 
blocking antibody (TSBAb, although these are rare). The destruction and fibrous 134 
replacement of the follicle cells lead to hypothyroidism. HT is significantly more 135 
frequent in individuals suffering concurrently from other autoimmune diseases like type 136 
1diabetes (T1D) or rheumatoid arthritis.  137 
In 1840 Carl-Adolph von Basedow termed the three typical clinical features in Graves’ 138 
disease (tachycardia, proptosis, and goiter) as the “Merseburg trias”. These symptoms 139 
are due to activated thyroid autoreactive CD4+ T cells that infiltrate the thyroid and 140 
activate B cells. The latter secrete TSH receptor (TSHR) stimulating antibodies (TSAb), 141 
which in turn induce thyrocyte proliferation and secretion of excess thyroid hormones 142 
and lead to hyperthyroidism. The autoimmune response, probably to the TSHR, leads 143 
to Graves’ orbitopathy (GO) which is characterized by proptosis or bulging eyes, also 144 
known as exophthalmos [12].  145 
The pathogenesis of AITDs is multifactorial including genetic predisposition for GD 146 
(Human Leukocyte Antigen (HLA) Class I molecules C*07 and B*08 as well as HLA 147 
Class II molecules DR3 and DRB1*08 [13], CD40, CTLA-4, PTPN22, FCRL3, 148 
thyroglobulin and TSHR, reviewed in [14]), pregnancy [4] and a variety of 149 
environmental factors (iodine and selenium intake, smoking, acute psychological 150 
stress [15-19] (Figure 2). Medication can also influence disease prevalence 151 
(amiodarone, certain monoclonal antibodies, interferon alpha, and cytokines). As 152 
autoimmune disorders tend to co-exist in the same subjects, celiac disease (CD) is 153 
associated positively with orbitopathy in GD patients [20]. In both CD and GO/GD T-154 
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helper cells 17 (Th17) play a role in pathogenesis [21-24]. Also, the cytokine IL-15 155 
which is involved in the differentiation of Th17 cells and links innate and adaptive 156 
immune systems is increased in the sera of Hashimoto thyroiditis (HAT) patients and 157 
was detectable in 33% of thyroid-associated ophthalmopathy (another name for GO) 158 
biopsies from extraocular muscles [25, 26].  159 
Characteristic for AITD are a Th1 pattern of immune response in HT and a 160 
predominance of T-helper cells 2 cytokines in GD, indicating a humoral pattern of 161 
immune reaction for the latter disease [27]. Furthermore follicular helper T (Tfh) cells - 162 
a relatively new subset of antigen-experienced CD4+ T cells found in B cell follicles of 163 
secondary lymphoid organs and serving as regulators in the evolution of effector and 164 
memory B-cell responses - are found to have an increased frequency in AITD. 165 
Therefore, this cell subset might also be important in the pathogenesis of AITD [28]. 166 
 167 
3. Function of commensal bacteria 168 
In AITD, the major body sites involved, apart from the thyroid, are the eyes and the 169 
skin, but nasal and oral microbiota might also be important for GO, considering its 170 
proximity to the orbit. Likewise, the gut as the most important reservoir of bacterial 171 
metabolism for the host and as the site with the highest numbers of immune cells is 172 
discussed in the following. The bacterial communities in these sites may have potential 173 
impact on AITD and to assess this, a precise characterization of the bacterial diversity 174 
and metabolic profile of commensal bacteria from healthy persons is needed.  175 
Due to its high vascularity, good lymphatic drainage, encapsulated position and its 176 
generation of hydrogen peroxide for the synthesis of thyroid hormone, the thyroid is 177 
remarkably resistant to infection and is rarely infected [29]. Under healthy 178 
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circumstances, the thyroid should be sterile. Apart from bacterial assessment in 179 
suppurative or non-suppurative infection, the authors are unaware of any analysis of 180 
bacteria carried out in thyroid tissue from healthy persons or AITD patients [30, 31].  181 
When assessing thyroid disease with ocular complications it is logical to focus mainly 182 
on the microbiota of the eye. However, there is neither an agreement about a naturally 183 
existing resident microbiota on the healthy ocular surface nor about the role resident 184 
microbiota may play at this site in ocular surface physiology [32]. Because of the high 185 
antimicrobial properties of the ocular surface, the bacterial abundance is innately low 186 
and organisms found, although normally classified as commensals, may play a more 187 
important role than in other sample sites with less bacterial abundance.  188 
The skin is the largest sensory organ of the body and harbors around 113 different 189 
bacterial phylotypes and the predominant microbiota on the skin was shown to 190 
correlate with lipid content, pH, sweat and sebum secretion [33]. The skin is 191 
predestined for complex ecological interactions with the environment and the skin 192 
microbiota perform several functions: i) inhibition of pathogen growth through 193 
antimicrobial peptides (bacteriocins (reviewed in [34]), microcins (reviewed in [35]) and 194 
phenol soluble modulins [36], ii) degradation of proteins associated with 195 
Staphylococcus aureus biofilm formation [37] and iii) decrease of the skin pH due to 196 
hydrolysis of sebum triglycerides by bacterial lipases and esterases [38-40]. The acidic 197 
milieu is unfavorable for many pathogens like S. aureus and Streptococcus pyogenes 198 
and thus the growth of coagulase-negative staphylococci and corynebacteria is 199 
supported [39, 41-43]. Furthermore, commensal bacteria tune the local cytokine 200 
production and influence regulatory T cells in the epidermis as well as mast cells [44-201 
47].  202 
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Despite the close proximity to the skin, the nasal cavity is populated differently and is 203 
one of the main reservoirs for S. aureus, a commensal organism carried by 20–30% of 204 
humans. Colonization is a risk factor for nosocomial infections with this bacterium [48].  205 
Gut commensals contribute to the host’s well-being in several ways. The microbiota 206 
influences both the innate and adaptive immune system by interacting with pattern-207 
recognition receptors such as the toll-like receptors (TLR) which are expressed on cells 208 
present in the gut wall, in particular the resident immune cells in the gut-associated 209 
lymphoid tissue (GALT). Microbial products activate the TLR and trigger the release of 210 
pro-inflammatory (TNFα, IL1 or IL6), anti- inflammatory (IL10) cytokines, or those 211 
which determine T lymphocyte phenotypes (IL17, IL23) [49, 50]. Commensal bacteria 212 
are able to actively induce regulatory responses in the gut epithelium. Regulatory T 213 
cells (Tregs), a subpopulation of T cells which maintain tolerance to self-antigens and 214 
prevent inflammatory and allergic responses, are induced via direct sensing of 215 
microbial organisms and their metabolites by dendritic cells or T cells. The luminal 216 
concentration of the bacterial metabolite butyrate positively correlates with the number 217 
of Treg cells in the colon [51] and besides other organisms, Clostridium spp. is able to 218 
create a transforming growth factor beta (TGF-β) rich environment and this supports 219 
Treg cell accumulation [52].They also perform a number of metabolic functions 220 
including food processing, digestion, and the synthesis of different products, e.g. 221 
vitamin B12 and short chain fatty acids (SCFA) as a main product of their metabolism 222 
[53]. SCFAs serve as an energy source for epithelial cells [54, 55], accelerate colonic 223 
transit through stimulation of the gut motility via serotonin [56, 57] and simultaneously 224 
regulate the sympathetic nervous system activity directly via the Gi/o protein-coupled 225 
receptor GPR41 at the level of the sympathetic ganglion [58]. Among the SCFAs, 226 
butyrate in particular modulates immunity and exerts an anti-inflammatory effect. This 227 
modulation is due to several effects including butyrate mediated reduction of nuclear 228 
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factor-κB and inhibition of histone deacetylase (HDAC) [59, 60]. HDAC prevents gene 229 
transcription by keeping chromatin in a compact form and its inhibition by SCFAs alters 230 
colonic gene expression and metabolic regulation [61]. Moreover, butyrate induces 231 
regulatory T cells in the colonic environment [51, 62, 63].  232 
The gut microbiota also protects the indigenous bacterial community against invasion 233 
by new and potentially harmful bacteria (colonization resistance) [64-68]. In this context 234 
secreted IgA may play a role via a process termed ‘antibody mediated 235 
immunoselection’ (AMIS) which shapes the composition of the microbiota.  It has been 236 
suggested that AMIS could be exploited by using antibodies to manipulate the 237 
microbiota and treat conditions caused by dysbiosis [69]. 238 
The gut microbiota impacts the central and enteric nervous systems [70] e.g. by 239 
producing neurotransmitters such as gamma-aminobutyric acid, serotonin, dopamine, 240 
noradrenaline and acetylcholine [71-75]. In turn neurotransmitters produced by the 241 
host can directly influence the composition of the gut microbiota [76-78], which may be 242 
relevant to the significantly higher levels of anxiety and depression reported in GD 243 
patients compared with those with goiter [79].  244 
It is logical that the gut microbiota will influence autoimmune conditions such as CD 245 
[80-82] and inflammatory bowel disease [83-89] and indeed Di Giacinto and colleagues 246 
suggested an amelioration of colitis severity using probiotic bacteria which induced an 247 
immunoregulatory response involving TGF-beta-bearing regulatory cells [90]. In their 248 
large multicenter study of new-onset pediatric CD, using samples from different sites, 249 
Gevers and colleagues observed a correlation of specific bacteria with disease status 250 
and especially the distinct microbial signature of the rectum at the disease onset offers 251 
unique potential for early diagnosis [91]. In CD, Tregs are induced by gliadin in situ 252 
[92]. Perhaps more surprising are the reports illustrating an impact of the gut microbiota 253 
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on autoimmune diseases targeting more distant sites e.g. T1D [93-99], rheumatoid 254 
arthritis [100-103] and the in vivo model of multiple sclerosis [104-106]. In the NOD 255 
mouse model the incidence of disease is maximal in the germ-free (GF) population 256 
whereas specific pathogen free mice are protected [96, 107]. The protective microbiota 257 
can be transferred from dam to pup [108] and the normally high T1D female-to-male 258 
sex bias in specific pathogen free (SPF) NOD mice can be equalized through fecal 259 
microbiota transplantation from male to female mice and its corresponding effects on 260 
testosterone levels [109, 110].  In the development of T1D in infants, gut microbiome 261 
analysis reveals a decrease in diversity once specific T1D autoantibodies were 262 
detectable but before the clinical onset of disease. This is accompanied by signs of 263 
intestinal inflammation through increased fecal human β-defensin 2 levels [111]. 264 
Interestingly, Vatanen and colleagues detected a connection between Bacteroides 265 
species-rich microbiota and simultaneously high T1D susceptibility in a human 266 
population potentially arising from a distinct microbiota-derived type of 267 
lipopolysaccharide with immunoinhibitory properties [112]. For a more general review 268 
on autoimmune-microbiota interactions the reader is referred to the following 269 
references [113, 114]. 270 
When compared to the human gut and other body sites, the oral cavity ranks second 271 
in total microbial load [115] and each bacterial species occupies highly specific niches 272 
differing in both anatomic location (such as the lips, cheek, palate, periodontal cavity 273 
and tongue) and nutrient availability [116]. The oral microbiota is regularly transferred 274 
to adjacent habitats via saliva, although only 29 out of 500 microbial taxa recovered 275 
from the mouth are cultivated from faecal samples [117]. Besides breaking down 276 
nutrients, the function of the oral microbiota is to modify the local pH or redox potential, 277 
the formation of biofilms and quorum sensing to coordinate these biofilms and gene 278 
expression [118].  279 
13 
 280 
4. Techniques  281 
This section discusses the methods used to assess the impact of bacteria in the onset 282 
and aggravation of autoimmune thyroid disease. For articles on mouse models (Banga 283 
and colleagues reported a model of GO based on genetic immunization using human 284 
TSHR A-subunit plasmid and close field electroporation. Induction of prolonged 285 
functional antibodies to the TSHR results in chronic disease with progression to GO-286 
like disease [119]) and segmented filamentous bacteria in thyroid autoimmunity please 287 
read elsewhere [120-123]. 288 
4.1 Culture-dependent techniques 289 
4.1.1 Conventional culture 290 
Until now, it has not been possible to cultivate and isolate bacteria directly from patients 291 
with AITD either from blood or tissue. However, culturing fecal microbial communities 292 
from healthy donors, under strict anaerobic conditions, enables capture of a 293 
remarkable proportion of the gut microbiota and preserves the distinctiveness of each 294 
donor`s microbiota [124]. These efforts resulted in the discovery of new taxa [125] and 295 
far more genetic potential to form spores than previously assumed [126]. Toft and co-296 
workers screened 107 fecal samples of GD patients for Y. enterocolitica (YE), but did 297 
not find an increased prevalence of YE. The isolation rate was very low (<1%) and 298 
similar to that observed in the local population with diarrheal illness [127]. A reliable 299 
animal model for GD/GO that reproduces all the aspects of the disorder has not been 300 
available, but very recently, Banga and colleagues reported a new mouse model of 301 
GO based upon immunogenic presentation of human TSHR A subunit plasmid by close 302 
field electroporation. Induction of prolonged functional antibodies to the TSHR results 303 
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in chronic disease with progression to GO [119]. In patients with dry eye syndrome 304 
(DES), a condition resulting from GO [128], Graham and colleagues performed a 305 
comparison of the bacterial community of the ocular surface in DES patients using 306 
conventional culture techniques and 16S rRNA gene PCR [129]. Coagulase negative 307 
staphylococci were found in both patients and controls, with an increase in culture 308 
positivity and mean numbers of bacteria in dry eye. The amount of identified bacterial 309 
genera and species was extended with molecular methods including potentially 310 
pathogenic bacteria such as Klebsiella spp. and repeated sampling and testing of a 311 
subset of patients revealed similar results. 312 
4.2 Models (in vitro) 313 
Using the example of intestinal autoimmune diseases like CD or inflammatory bowel 314 
disease (IBD) and other autoimmune diseases like primary biliary cirrhosis [130] the 315 
use of in vitro models in GD can generate knowledge and better understanding of the 316 
disease although all of the models have their limitations and thus do not always 317 
correlate in detail with pathophysiological conditions in a human body. 318 
4.2.1 Cell lines 319 
Monolayers of intestinal cell lines are composed of a single cell type and lack the 320 
variety found in the intestine, e.g. goblet cells and paneth cells and their crosstalk with 321 
other cells of the body. Nevertheless, Caco-2 cells are widely used to study CD and 322 
IBD and increase understanding of pathogenesis. In CD, Caco-2 cells exposed to 323 
gliadin proliferate, display actin rearrangements and inhibition of spontaneous 324 
differentiation [131]. In addition they have demonstrated how 1) patients’ serum 325 
antibodies modulate the epithelium and 2) bifidobacteria inhibit the toxic gliadin effects 326 
[132, 133]. Other intestinal cell lines e.g. T84 and HT29 express IBD related cell 327 
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surface molecules (CD40) after treatment with cytokines [134]. Caco-2 cells have been 328 
used to investigate the beneficial effect of different commensal gut bacteria on anti-329 
inflammatory G protein–coupled receptors expressed by intestinal cells [135] and also 330 
probiotics were co-cultured with this cell line: Mattar and co-workers showed that 331 
Lactobacillus casei up-regulates mucin gene expression [136].  332 
The combination of Caco-2 cells in a transwell system with dendritic cells or THP-1 (a 333 
human monocytic cell line derived from an acute monocytic leukemia patient) provides 334 
a more physiological setting. It allows measurements of cytokine production and tight 335 
junction protein expression in response to commensal or pathogenic bacteria as well 336 
as CD triggering gliadin [137-139].  337 
Patient-derived T-cell lines and clones from the site of inflammation or peripheral blood 338 
are widely used in CD and provide information on T cell activation in the lamina propria 339 
to specific antigens and T cell infiltration into the intestinal epithelium [140-142]. In GD, 340 
Roura-Mir and colleagues analysed lymphocytes from peripheral blood and thyroid 341 
lesions ex vivo to investigate the role of CD1-restricted T cells, which are able to 342 
present self and foreign lipid antigens to T cells. They suggested a possible effector 343 
function of CD1-restricted T cells in tissue destruction [143]. In a cell proliferation assay 344 
with peripheral blood mononuclear cells (PBMCs) cellular reactivity to Yersinia outer 345 
membrane proteins (YOP) encoded by a 72-kilobase virulence plasmid of YE was 346 
present in GD patients and controls whereas intrathyroidal lymphocytes obtained from 347 
GD patients demonstrated marked proliferation in response to the released proteins 348 
[144].  349 
 350 
4.2.2. Mucosal biopsy organ culture 351 
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Culturing mucosal biopsies, with their histological architecture intact, allows in vivo 352 
processes to be studied in controllable conditions outside the body (ex vivo). In the 353 
past, Ussing chambers have been widely used to monitor net ion transport across living 354 
epithelium in mice and humans [145, 146]. Another approach is to study intestinal 355 
biopsies of IBD patients, in which apical to basolateral polarity is maintained by a “glued 356 
cave cylinder” to facilitate stimulation of each border in turn [147]. In CD, the 357 
importance of IL-15 was demonstrated in a culture of duodenal biopsy [148], whilst an 358 
organ culture demonstrated an impaired mucosal immune response to gliadin in T1D 359 
[149]. Ogino and colleagues showed that in Crohn’s disease, CD14(+) CD163(low) 360 
cells, from the intestinal lamina propria of patients, induce the differentiation of naive T 361 
cells into Th17 cells and by doing this contribute to the pathogenesis of CD and 362 
possibly other Th17-associated diseases [150].  363 
4.2.3 Flow models 364 
Chambers of flow systems allow co-culture of different cell types in separate chambers; 365 
proteins and signals produced by one cell type can flow through the system to have an 366 
effect on another cell type, as would happen in the body. To date perfusion flow studies 367 
have not been applied to autoimmune disease, but given their utility it is only a matter 368 
of time until they are used to study AITD.  369 
However, there are many examples of the use of flow in the culture of different 370 
mammalian cells [151-153].  371 
4.2.4 3D cell culture systems 372 
In addition to the use of flow to better mimic conditions in vivo, there is also a growing 373 
trend moving away from culture on 2D surfaces and into 3D scaffolds and gels. In a 374 
model for H. pylori infection, primary gastric glands were grown in Matrigel as a 3D 375 
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spheroid; morphological features of typical stomach tissue were evident and spheroids 376 
survived for greater than 9 months [154]. Collagen gels have been used for the 3D co-377 
culture of rat intestinal sub-epithelial myofibroblasts with a rat intestinal epithelial cell 378 
line [155]. A simple 3D co-culture model of the gut used non-transformed human 379 
neonatal small intestinal cells and non-transformed human monocyte/macrophages for 380 
the study of the interaction of Lactobacillus spp. with the gut [156]. 381 
4.2.5 Intestinal models  382 
To rebuild the intestine in a larger format than those mentioned above, in vitro models 383 
can include short-term batch incubators, single stage reactors through to multistage 384 
continuous systems and their evolutions (simulator of human intestinal microbial 385 
ecosystem (SHIME), EnteroMix, TNO (gastro-) Intestinal Models (TIM) and PolyfermS) 386 
have been developed [157-162]. The more complex models can mimic the microbiota 387 
and their fermentation processes in different parts of the human gut and enable 388 
evaluation of a wide range of environmental regulators of bacterial activity like 389 
substrate availability, pH and growth rates. Advantages of these systems are the lack 390 
of ethical issues surrounding sampling the human gastrointestinal tract and 391 
surrounding the use of radioactive or toxic substances. Running multi-compartment 392 
continuous systems is relatively inexpensive and microbial community development in 393 
dynamic models after inoculation with faecal microbiota is reproducible [159]; this holds 394 
true even for faecal samples of persons with high/low conversion rates of organic 395 
materials into energy sources by bacteria [163]. Obvious disadvantages of the 396 
intestinal models are the lack of physiological host environment with epithelial cells, 397 
immune cells and mucus. To help counteract this, MacFarlane and colleagues added 398 
mucin to their model [164] and combined dynamic models with cell culture systems by 399 
adding fermentor vessel effluent onto Caco-2 cells [165]. Other groups investigated 400 
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the effects of the culture effluent on immune cells in the macrophage cell line U937 401 
[166]. Besides inoculation with healthy adult faeces diluted with phosphate buffered 402 
saline, Cinquin and co-workers used immobilized infant faeces on gel beads [167]. 403 
Other authors inoculated their gut models with faecal samples derived from IBD 404 
patients or from healthy individuals resulting in an increased production of toxic 405 
metabolites by IBD microbiota [83]. Also shortened transit time, which is common in 406 
irritable bowel syndrome, has been investigated [168]. By mimicking an overgrowth 407 
with Clostridium difficile after antibiotic treatment, van Nuenen et al. observed a two-408 
fold increase of toxic proteolytic metabolites which could be neutralized by the addition 409 
of different inulins, a  group of naturally occurring plant polysaccharides and a 410 
functional food that stimulates the growth of healthy bacteria (= prebiotics) [169]. 411 
Probiotics, prebiotics, their synergistic effects and other dietary components have been 412 
studied in intestinal models with the aim of increasing the levels of beneficial microbes 413 
[170-174]. In the SHIME model, van den Abbeele and colleagues incorporated mucin-414 
covered, simplified ecosystems (microcosms) and assessed the long term colonization 415 
of lactobacilli and their stability under antibiotic treatment with tetracycline, amoxicillin 416 
and ciprofloxacin [175]. More recent developments for intestinal models include the 417 
Host-Microbiota Interaction module for long-term incubation [176] and the “gut-on-a-418 
chip” [177]. 419 
Intestinal models enable the user to perform mechanistic studies in vitro and to develop 420 
hypotheses. Nonetheless, intestinal models will always require validation in vivo due 421 
to the complexity of host-associated environments.  422 
 423 
4.3 Culture-independent techniques 424 
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4.3.1 Antibody and antigen detection 425 
Serological tests like agglutination, enzyme linked immunosorbent assay (ELISA) and 426 
Western blot (WB) as well as antigen detection tests in serum and stool or in the form 427 
of radio-labelled urea breath test for H. pylori detection have been used to explore the 428 
possible link between AITD and bacteria by measuring antibodies against bacterial 429 
antigens which could induce cross-reactive immune response against self-antigens. 430 
Besides genetic predisposition, 25% of the predisposition to Graves’ disease is 431 
estimated to be linked to environmental factors like infections [178]. Since the 1970s 432 
and until more recently, infections with the bacterium YE have been implicated in the 433 
pathogenesis of GD caused by increased YE antibody prevalence in GD patients [179-434 
182], but this was not reproduced by all groups [183-185] (see Table 1 and Figure 1). 435 
Also prospective studies on this field were undertaken with different outcomes: a case-436 
control twin study and two studies in euthyroid females related to AITD patients 437 
with/without follow up revealed no causal relationship between YE infection and 438 
autoimmune thyroid disease [184-186]. However, in earlier studies with similar design 439 
a higher prevalence of antibodies against YOP was measured [187, 188]. A linear 440 
correlation between YE antibodies and antibodies against TSHR, thyroglobulin and 441 
thyroid-peroxidase has been described [189]. YE antigens not only display high-affinity 442 
binding sites for the hormone TSH and the TSHR Abs from patients with Graves’ 443 
disease, but also show a sequence homology between its outer membrane porins 444 
(Omp) [190, 191] and the TSHR. In their study with mice, Luo and colleagues produced 445 
antibodies against the purified extracellular domain of human TSHR and showed that 446 
anti-TSHR antibodies reacted with the envelope antigens of YE. When mice were 447 
immunized with YE, anti-TSHR-antibodies were induced [192], supporting the concept 448 
of molecular mimicry. Hargreaves and co-workers demonstrated that a recombinant 449 
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Fab germline fragment of a monoclonal TSAb from GD mice doesn´t recognize TSHR, 450 
but does bind YE outer membrane porins [193].  451 
The impact of antibodies to Helicobater pylori (HP) on GD was first observed in 1999 452 
[194]. Similar to YE, some groups were able to show a significant increase in HP 453 
antibody prevalence and some not [195-200]. In the case of no significant difference 454 
in anti-HP-IgG a significant association between AITD and cytotoxin-associated gene 455 
A (CagA)-antibodies and between GD and CagA-antibodies was observed [200]. 456 
Interestingly, Bertalot et al. screened patients after HP eradication and found a 457 
reduction in the anti-thyroid peroxidase titre, in anti-thyroglobulin and a partially 458 
normalized anti-TSHR titre [201].  459 
Besides these two organisms, Borrelia burgdorferi and the neurotoxin of Clostridium 460 
botulinum have also been implicated in the context of GD suggesting that antigens 461 
cross-reacting with human TSHR share multiple antigenic epitopes with other bacterial 462 
antigens [202-205].  463 
Glycoproteins of the probiotic bacterium Bifidobacterium bifidum were shown to have 464 
an immunological similarity with thyroid peroxidase and thyroglobulin, pointing towards 465 
a possible role in the pathogenesis of AITD [206]. Nevertheless, several years earlier, 466 
Zhou and colleagues ruled out the induction of pathological inflammation in a mouse 467 
model of experimental autoimmune thyroiditis due to a bacterium of the same genus, 468 
namely Bifidobacterium lactis [207].  469 
Viruses and their role in AITD have also been discussed and corresponding nucleic 470 
acid has been detected via PCR-based methods and immunochemistry [30, 31, 208], 471 
but viruses are beyond the scope of this review.    472 
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Overall, a large number of studies showed epidemiological, serological and molecular 473 
evidence that YE and other bacteria are potentially important in the pathogenesis of 474 
AITD and GD. None of the studies showed a direct correlation of bacterial infection to 475 
the development of AITD and most patients with one of the above mentioned bacterial 476 
infections (including those who produce anti-TSHR antibodies) do not develop GD 477 
[209]. It might be possible that the ability to produce anti-TSHR antibodies in response 478 
to YE antigens homologous to the TSHR persist only in susceptible individuals with the 479 
YE antigens acting as a trigger to the disease development. Further studies are needed 480 
to get a definite answer.  481 
4.3.2 A possible link between microbiota and autoimmune thyroid 482 
Over the last decade, sophisticated sequencing techniques and high throughput 483 
technologies have become affordable and allowed both characterizations of the 484 
microbes living in and on the human host as well as their metabolic functionality. The 485 
Human Microbiome Project elucidated the structure and diversity of the healthy human 486 
microbiome at almost 20 different body sites and by doing this created a large 487 
reference database [210].  488 
Alterations in the gut microbiota have already been observed for many diseases 489 
ranging from diabetes, alcoholic liver disease and psychiatric disorders to cancer and 490 
autoimmune diseases. Numerous studies have been performed within the autoimmune 491 
sector regarding the gastrointestinal tract, joints and the neural system, but very little 492 
is available for AITD, the most frequent of the autoimmune diseases. Studies 493 
examining the microbiome of AITD patients and especially with GD/GO are not 494 
available, but many microbiome studies investigating the impact of known risk factors 495 
such as genetic risk factors (gender) and environmental risk factors (smoking, stress) 496 
have been undertaken (see Figure 2). Also studies on body sites actually or possibly 497 
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involved in GD/GO like eye, nose, throat and intestine have been performed and all 498 
are addressed in this section.  499 
Risk factors to consider  500 
1. Gender and genetics 501 
The unequal gender distribution in autoimmune disease has been covered in 502 
many publications, but only a few tried to characterize the gut microbiome of 503 
females and males to look for differences. Flow cytometry-based in situ 504 
hybridizations revealed higher levels in Bacteroides and Prevotella in males 505 
than in females with autoimmune disease, but no gender effects could be 506 
observed for any other bacteria [211]. Markle et al. entered the topic more 507 
deeply with the help of NOD mice [109]. Normally, the incidence of T1D is higher 508 
in female NOD SPF mice than in male. Whilst in germ free (GF) mice the 509 
incidence is equal between the two genders. Serum testosterone levels were 510 
higher in female GF mice than in SPF and higher in male SPF mice than in GF 511 
suggesting that colonization by commensal microbes elevates testosterone 512 
levels in males and may protect NOD males from developing T1D. 513 
Transplantation of the male microbiota to females resulted in altered recipient´s 514 
microbiota and consequently elevated testosterone levels and changes in 515 
metabolite production. Furthermore, the T1D diagnostic parameters islet 516 
inflammation and autoantibody production were decreased. Yurkovetskiy and 517 
colleagues obtained similar results in the same NOD mouse model before and 518 
after puberty: their 16S rRNA gene profiles indicate that the gut microbial 519 
communities depend on the gender of post-pubescent mice. After castration, 520 
female and castrated male microbiota are more similar to each other than to 521 
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non-castrated male microbiota. The microbiota differs in males and females 522 
after GF mice have been colonized with a female SPF microbiota [110].  523 
In a large study with more than 400 twin pairs, Goodrich and colleagues 524 
characterized the gut microbiomes of monozygotic twins and found them to be 525 
more similar than those of dizygotic twins [212], Christensenellaceae belonging 526 
to the Firmicutes was the taxon with the highest heritability. Evidence from mice 527 
also suggests that the genetics of the host strongly influences the microbiome 528 
of the gastro-intestinal tract [213] and has also shown that variation in the 529 
microbiome influences disease outcomes, e.g. the occurrence of T1D in non-530 
obese diabetic (NOD) mice or the induction of experimental autoimmune 531 
encephalomyelitis [106, 108]. 532 
The intestine is the largest immune organ in the body and is comprised of 533 
trillions of commensal organisms and is affected by treatment (antibiotics, 534 
corticosteroids) [214, 215] and diets among others.  535 
Furthermore, genetic investigations demonstrated a connection between CD 536 
and GD [216, 217] and also T1D organ culture studies indicate an unbalanced 537 
mucosal immune response to gliadin [149]. 538 
 539 
 540 
 541 
2. Pregnancy 542 
The prevalence of GD in pregnancy is rare and ranges between 0.1% and 1% 543 
[218]. In pregnancy, the gut microbiome changes each trimester [219] and 544 
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pregnant women have increased total bacteria and Staphylococcus numbers 545 
which seems to be related to increased plasma cholesterol levels. The mothers’ 546 
body weights also seems to be of importance because reduced numbers of 547 
some anaerobes (Bifidobacterium and Bacteroides) and increased numbers of 548 
other anaerobic bacteria (Staphylococcus, Enterobacteriaceae and Escherichia 549 
coli) were detected in overweight compared to normal-weight pregnant women 550 
[220]. In pregnant mice it has been shown recently that changes in the maternal 551 
gut microbiota are dependent upon the mother's periconceptional diet but not 552 
upon increases in maternal weight gain during pregnancy [221]. 553 
3. Smoking 554 
Smoking alters the oropharyngeal and tracheal environment in smokers 555 
compared to non-smokers, but in 2013 Biedermann and co-workers suggested 556 
an effect of smoking also on the gut microbiota [222, 223]. The group found an 557 
increase of Firmicutes and Actinobacteria and a non-significant decrease of 558 
Bacteroides and Proteobacteria with simultaneous increase in microbial 559 
diversity after smoking cessation. Bacteroidetes seems to be the only phylum 560 
with a significant change only after 4 weeks of smoking cessation maintained 561 
through to eight weeks. Principal component analysis separated the bacterial 562 
community composition of the smoking cessation group clearly from the control 563 
group, particularly between before and after smoking cessation. 564 
4. Stress, anxiety 565 
As discussed in an earlier section, stress can modify the microbiota composition 566 
and vice versa [68, 70, 77-79]. 567 
Body sites to consider 568 
25 
1. Nose 569 
Despite the close proximity of the nose to the eyes, the role of the nasal 570 
microbiota in the pathogenesis of AITD has not been examined. Most of the 571 
studies compared the nasal microbiome of healthy persons [210, 224-227] with 572 
those of persons with chronic rhinosinusitis and other nasal inflammatory 573 
diseases [228-232]. Partially, these investigations included additional cultural 574 
assessment of the microbiome [225, 229, 231] and samples were taken from 575 
the depth of the sinus of patients undergoing endoscopic sinus surgery [231, 576 
232]. The healthy nasal microbiome consists of mainly staphylococci 577 
(coagulase-negative staphylococci, Staphylococcus aureus), corynebacteria, 578 
propionibacteria and Moraxella spp., whereas between the studies of nasal 579 
inflammation, there is no apparent consensus [210]. The nasal microbiota differs 580 
seasonally and the diversity decreases within the first year of life [233]. Also 581 
Graves' disease tends to vary seasonally with more frequently relapses in spring 582 
and summer [234]. Further studies are needed to reveal possible relationships 583 
between the microbiota and disease progression.  584 
2. Eye 585 
Clinically recognized GO occurs in about 50% of GD patients and therefore a 586 
comparison of the eye microbiota in these patients would be helpful, but has not 587 
been done yet [12]. In a mouse model of autoimmune uveitis, it was recently 588 
shown that activation of retina-specific T cells is dependent on gut microbiota-589 
dependent signals [235].  590 
3. Skin 591 
1.5% of GD patients suffer from pretibial myxedema (PM) and other GD related 592 
skin disorders [236]. Characteristic for PM are skin thickening especially in the 593 
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pre-tibial area, but the disorder can also occur in other areas. No study focused 594 
particularly on the skin microbiota in patients with GD and subsequent skin 595 
disorders, although there is evidence that the skin microbiota varies in primary 596 
immunodeficiency [237] and also in skin (affecting) disorders like psoriasis [238, 597 
239], atopic dermatitis [240], systemic lupus erythematosus [241] and Morbus 598 
Behcet [242].  599 
4. Throat 600 
Several diseases except AITD have been linked to the commensal bacterial 601 
population in the human mouth. In RA, Zhang and colleagues observed a 602 
concordance between the gut and oral microbiomes in patients with RA and a 603 
dysbiosis which was partially resolved after treatment [103]. Also in Sjögren’s 604 
syndrome, a systemic autoimmune disorder characterized by lymphocytic 605 
infiltrates in exocrine organs, altered bacterial communities have been noticed. 606 
Szymula and colleagues showed the ability of peptides originating from oral and 607 
gut bacteria activating Sjogren's syndrome Antigen A (SSA)/Ro60-reactive T 608 
cells [243, 244].       609 
5. Gut 610 
In autoimmune thyroid disease the link between microbiota and disease onset 611 
or progression has not been elucidated yet. However, possible relations should 612 
be pointed out: already in 1988, Penhale and Young found in a rat model of 613 
autoimmune thyroiditis that modulation of the gut microbiota results in a 614 
significant influence on susceptibility to thyroid autoimmunity [245]. According 615 
to them, SPF rats were markedly less susceptible to the induction of 616 
experimental autoimmune thyroiditis by thymectomy and irradiation than 617 
conventionally reared rats of the same strain. Additionally, the incidence of 618 
thyroid lesions indicating thyroiditis as well as measured autoantibodies 619 
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increased in conventional rats and the offspring of conventional reared mothers 620 
were more susceptible to develop autoimmunity. 27 years later, a PCR-621 
denaturing gradient gel electrophoresis with universal primers targeting V3 622 
region of the 16S rRNA gene and quantitative real-time PCR revealed a different 623 
intestinal microbiota composition in hyperthyroid patients compared to controls 624 
whereas hypothyroidism leads to bacterial overgrowth in the small intestine 625 
assessed by hydrogen glucose breath test [246, 247]. Both, hyperthyroidism 626 
and hypothyroidism often go hand in hand with thyroid autoimmunity. Not only 627 
the microbiota composition, but also its enzyme activities have to be considered: 628 
glucuronidases responsible for provision of conjugated thyroxine are mostly of 629 
bacterial origin [248, 249]. Regarding the ability to produce hormones, the gut 630 
microbiota “has the potential to produce hundreds of products. From a 631 
morphological and biochemical perspective, it is far larger and more 632 
biochemically heterogeneous than any other endocrine organ in man” [250]. T4 633 
malabsorption can be due to diverse gut microbiota in patients with CD and 634 
lactose intolerance [251, 252]. Similar to patients with T1D, a morphological and 635 
functional damage of the intestinal barrier was found [253] [254, 255].  636 
In 2009, Oresic and colleagues investigated the contribution of the gut 637 
microbiota to lens and retinal lipid composition. In their comprehensive lipidomic 638 
profiling of lens and retina from conventionally raised and GF mice the authors 639 
found a decrease of lens phosphatidylcholines in the presence of gut microbiota 640 
due to an increased exposure to oxidative stress than in GF mice [256].  641 
In summary, the questions dominate the answers concerning the impact of the 642 
microbiota in AITD and there is room for future research on this topic.  643 
 644 
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5. Conclusion 645 
Interactions between the host and the gut microbiota influence host immunity and 646 
physiology and therefore are important to maintain intestinal homeostasis. Disruption 647 
of these host–microbial interactions due to dysbiosis can alter this balance leading to 648 
disease. Currently, very little is known about the impact of bacteria and microbiota in 649 
autoimmune thyroid disease. The author and co-authors are engaged in the project 650 
“Investigation of Novel biomarkers and Definition of the role of the microbiome In 651 
Graves’ Orbitopathy” (INDIGO), which is part of the Industry-Academia Partnerships 652 
and Pathways (IAPP) program in People Marie Curie Actions (FP7-PEOPLE-2013-653 
IAPP). The project aims to identify prognostic biomarkers to facilitate early preventative 654 
intervention, to investigate the role of the microbiome on disease progression and to 655 
assess the impact of probiotics in disease reduction. Hopefully, results will answer 656 
these questions and provide insight into the influence of environmental factors on 657 
gene–microbe interactions and the potential role of intestinal bacteria in the onset and 658 
progression of Graves’ disease.  659 
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Table 1  1372 
Bacterium Cohort Antibodies Method Antibody prevalence in patients in comparison to controls Reference  
      
H. pylori GD and HAT anti- HP (IgG) ELISA, rlUBT no sign. Difference [257] 
H. pylori AITD anti- HP, anti-CagA WB increase in AITD (p=0.006) [194] 
H. pylori HAT anti-CagA (IgG) ELISA, rlUBT No sign. difference [199] 
H. pylori AITD anti- HP ELISA increase (p=0.032) [195] 
H. pylori GD anti-CagA (IgG), HP-antigens (stool) ELISA increase (p=<0.001) with positive AEIA; increase in anti-CagA (p=<.005) [196] 
H. pylori GD and HAT anti-CagA (IgG), HP-antigens (stool) ELISA Đorrelation ďetween HP ;p≤Ϭ.ϬϬϬϭͿ and Cag-A ;p≤Ϭ.ϬϬ5Ϳ in GD, not in HAT [197] 
H. pylori AITD anti- HP (IgG), anti-CagA WB no sign. difference in anti-HP-IgG, association between CagA-antibodies and AITD [200] 
H. pylori Blood donors anti-HP (not specified) EIA increase in donors with thyroid autoantibodies (p=0.018) [198] 
Y. enterocolitica GD anti-YE agglutination (Gruber-Widal) increase (p<0.005) [179] 
Y. enterocolitica Thyroid disease anti-YE agglutination (Gruber-Widal) present in 42% of 36 patients with thyroid disease and in none of 77 controls [182] 
Y. enterocolitica AITD anti-YE 0:3 and 0:9 (IgM, IgA, IgG), YP ELISA anti-YE IgA 0:3 increased (p<0.01), no difference in IgM and IgG   [258] 
Y. enterocolitica GD and HAT anti-plasmid YE proteins (IgA, IgG) WB increase in anti-immunogenic protein, IgA and IgG in GD and HAT (p<0.01; p<0.001) [259] 
Y. enterocolitica GD and HAT anti-YE 0:3, 0:5, 0:6 and 0:9 micro-agglutination anti-YE 0:3 not significantly different, anti-0:5 increase in GD and HAT (p<0.001) [260] 
Y. enterocolitica GD and HAT anti-YE 0:3 agglutination (Gruber-Widal) increase in GD (p=<0.01), no significant increase in HAT [261] 
Y. enterocolitica GD and HAT anti-YOP2-5 WB, PBMC proliferation assay   YOP2-5 antibodies found in GD (96%), HAT (55,5%) and controls (70,8%) [144] 
Y. enterocolitica GD and HAT anti-YE 0:3 and 0:9 agglutination (Gruber-Widal), ELISA no difference, thyroid therapy didn't change immunreactivity  [183] 
Y. enterocolitica GD and HAT anti-YE 0:3, 0:5, 0:8 and 0:9 agglutination (Gruber-Widal) increase in GD (p=<0.05)  [189] 
Y. enterocolitica AITD anti-YOPs 0:9 (IgA and IgG)   WB increase of IgA and IgG antibodies against YOPs (p<0.05 and p=0.002, respectively) [187] 
Y. enterocolitica AITD anti-YOPs 0:9 (IgA and IgG)   WB no difference [184] 
Y. enterocolitica GD anti-YOPs 0:9 (IgA and IgG)   WB increase in IgA and IgG (p=0.054 and p=0.043, respectively)  [178] 
Y. enterocolitica GD and HAT anti-YOPs 0:9 (IgA and IgG)   WB no difference [186] 
Y. enterocolitica AITD anti-YOPs 0:9 (IgA and IgG)   WB no difference [185] 
B. burgdorferi GD and HAT anti-BB (IgG) ELISA no difference [204] 
B. henselae HAT anti-BH (IgG) IFAA increase, case report  [262] 
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Table 1: Evaluation of anti-bacterial antibody prevalence in patients with autoimmune 
thyroid disease (AITD), Graves’ disease (GD) and Hashimoto thyroiditis (HAT) with 
different test methods. Abbreviations: cytotoxin-associated gene A (CagA), 
Helicobacter pylori (HP), Yersinia enterocolitica (YE), Yersinia outer proteins (YOP), 
enzyme-linked immunosorbent assay (ELISA), western blot (WB), radiolabeled urea 
breath test (rlUBT), immunofluorescent antibody assay (IFAA), peripheral blood 
mononuclear cells (PBMC).   
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Role of bacteria in autoimmune thyroid disease:  publications on this topic 
focusing on the five most cited bacterial organisms. 
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Figure 2 
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Figure 2: Overview of the main environmental factors influencing Graves`disease. 
Environmental factors affect bacterial populations at different body sites and 
therefore potentially contribute to the development of Graves’ disease and 
orbitopathy.       
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